| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 02/10/2005 | WO2005011605A2 Combination therapies for multiple sclerosis |
| 02/10/2005 | WO2005011599A2 Antibodies specific for toxic amyloid beta protein oligomers |
| 02/10/2005 | WO2005011590A2 Compositions and methods for restoring sensitivity to treatment with her2 antagonists |
| 02/10/2005 | WO2005011580A2 Compositions and methods for herpes simplex prophylaxis and treatment |
| 02/10/2005 | WO2005011376A2 Altered antibodies having improved antigen-binding affinity |
| 02/10/2005 | WO2005000896A3 Polypeptides that bind an anti-tissue factor antibody and uses thereof |
| 02/10/2005 | WO2004111081A3 Antigenic peptides of sars coronavirus and uses thereof |
| 02/10/2005 | WO2004107618A3 Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof |
| 02/10/2005 | WO2004091657A3 Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
| 02/10/2005 | WO2004065416A3 Synthetic antibody phage libraries |
| 02/10/2005 | WO2004050016A3 Delivery of pharmaceutical agents via the human insulin receptor |
| 02/10/2005 | WO2004043332A3 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
| 02/10/2005 | WO2004033630A3 Modified hepsin molecules having a substitute activation sequence and uses thereof |
| 02/10/2005 | WO2004024068A3 Novel composition and methods for the treatment of immune related diseases |
| 02/10/2005 | WO2003086175A8 Compositions and methods for the therapy and diagnosis of lung cancer |
| 02/10/2005 | WO2003025117A3 Cloning and sequencing of pyruvate decarboxylase (pdc) genes from bacteria and uses therefor |
| 02/10/2005 | WO2002064626A3 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 02/10/2005 | WO2002020718A3 Osteoclast-associated receptor |
| 02/10/2005 | WO2000024869A9 Methods for modulating cell fusion |
| 02/10/2005 | US20050033034 Anti-t cell immunotoxin fusion protein and its therapeutic use |
| 02/10/2005 | US20050033033 Chimeric immunoglobulin for use in preventing and treating diseases associated with caspase aberration; immunotherapy and tissue engineering |
| 02/10/2005 | US20050033031 Methods for humanizing rabbit monoclonal antibodies |
| 02/10/2005 | US20050033030 Humanised antibodies and uses thereof |
| 02/10/2005 | US20050033029 Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses |
| 02/10/2005 | US20050033028 Reducing immunogenicities of immunoglobulins by framework-patching |
| 02/10/2005 | US20050033018 Receptors and membrane-associated proteins |
| 02/10/2005 | US20050032978 Copolymer of isobutylene with carbamate groups which is curable |
| 02/10/2005 | US20050032834 Administering a chloroquine compound as an anticarcinogenic, antiischemic, anticholesterol, or anxiolytic agent |
| 02/10/2005 | US20050032696 Muscle transcription factors |
| 02/10/2005 | US20050032693 Novel polypeptides, their nucleic acids, and methods for their use in angiogenesis and vascularization |
| 02/10/2005 | US20050032691 Methods for treating glaucoma |
| 02/10/2005 | US20050032216 Plasmid comprising antibody specific for cell surface membrane protein receptor (5T4) for use in tissue directed treatment of tumors; tissue targeted therapy |
| 02/10/2005 | US20050032190 Beta-secretase substrates and uses thereof |
| 02/10/2005 | US20050032185 3-phosphoinositide-dependent protein kinase that phosphorylates and activates protein kinase B alpha; drug target for cancer; drug screening for enzyme inhibitors as anticancer agents |
| 02/10/2005 | US20050032175 High affinity fusion proteins and therapeutic and diagnostic methods for use |
| 02/10/2005 | US20050032174 Multimeric protein for use in the treatment and prevention of infection and bleeding disorders |
| 02/10/2005 | US20050032172 Expression vector comprising nucleotide sequences coding tumor necrosis factor (FTHMA-) and/or axon guidance receptor (T85) for use in identifying modulators for prevention and/or treatment of cell proliferative or neurological disorders |
| 02/10/2005 | US20050032170 Expression vector comprising nucleotide sequences coding native sequence-4 (NS4) for use in identifying modulators for treatment and prevention of obesity, cachexia and anorexia |
| 02/10/2005 | US20050032168 17 human secreted proteins |
| 02/10/2005 | US20050032161 Novel xanthine phosphoribosyl transferase |
| 02/10/2005 | US20050032158 Using novel g-protein coupled taste receptor (T1R2) as tools in identifying modulators to use as additives which enhance sweetness of foods consumed by animal and humans |
| 02/10/2005 | US20050032155 Expression vector comprising nucleotide sequences coding defective receptor protein for use as model in treatment and prevention of convulsive disorders |
| 02/10/2005 | US20050032134 Neoplasm-specific polypeptides and their uses |
| 02/10/2005 | US20050032133 Method of determining whether a patient afflicted with cancer can be treated by a therapeutic agent that targets the 17-1a antigen |
| 02/10/2005 | US20050032132 Cancer diagnostics |
| 02/10/2005 | US20050032131 Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases |
| 02/10/2005 | US20050032123 Oncoprotein protein kinase |
| 02/10/2005 | US20050032117 Method for assessment of cystic lung fibrosis |
| 02/10/2005 | US20050032114 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| 02/10/2005 | US20050032111 Using intregral membrane protein concentration as diagnostic and/or prognostic indicator of successful pregnancy; in vitro fertilization and reproductive disorders |
| 02/10/2005 | US20050032109 Polypeptide activator for use as tool in treatment of thrombosis; treatment diagnosis of blood disorders |
| 02/10/2005 | US20050032107 Method of screening anti-mycobacterial molecules |
| 02/10/2005 | US20050032103 Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus |
| 02/10/2005 | US20050032101 Methods for diagnosis and therapy of cancer and composition useful therein |
| 02/10/2005 | US20050032085 Novel chromophores/fluorophores and methods for using the same |
| 02/10/2005 | US20050032059 Genetically modified hydrolase comprising enhanced activity for use in hydrolysis of starch to glucose; textile treatment; preparation of animal feeds |
| 02/10/2005 | US20050032047 Comprises peptide for genotyping and detecting hepatitis viral infection; immunoassay |
| 02/10/2005 | US20050031647 Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof |
| 02/10/2005 | US20050031643 Microorganisms for therapy |
| 02/10/2005 | US20050031635 Inducing specific B cell anergy to an immunogen comprising a conjugate of a nonimmunogenic valency platform molecule and an analog of the immunogen that (a) binds specifically to B cells to which the immunogen binds and (b) lacks the T cell epitope(s) of the immunogen |
| 02/10/2005 | US20050031634 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 02/10/2005 | US20050031633 Glucan binding protein and glucosyltransferase immunogens |
| 02/10/2005 | US20050031629 An immunogenic A beta fragment linked to a carrier molecule to form a conjugate, wherein the carrier molecule promotes an immune response comprising antibodies to the A beta fragment; Alzheimer's disease; antibodies |
| 02/10/2005 | US20050031628 Chimeric antigens for breaking host tolerance to foreign antigens |
| 02/10/2005 | US20050031627 Methods for preparing immunoconjugates |
| 02/10/2005 | US20050031626 Binding agents with differential activity |
| 02/10/2005 | US20050031625 First antibody binds CR1 receptor coupled to second antibody that binds to protective antigen component of anthrax toxin, but does not inhibit the binding of the protective antigen component of the anthrax toxin to cells |
| 02/10/2005 | US20050031624 Monoclonal antibodies to human immunodeficiency virus and uses thereof |
| 02/10/2005 | US20050031623 Blot analysis of urine/serum; proteoglycan-like domains; oncogenes; hybridomas |
| 02/10/2005 | US20050031622 Treatment and diagnosis of cancer using inositolphosphoglycans antagonists |
| 02/10/2005 | US20050031621 For treament of neoplasia; competitive binding |
| 02/10/2005 | US20050031620 Combined cancer treatment methods using selected antibodies to aminophospholipids |
| 02/10/2005 | US20050031619 Therapeutic compositions that alter the immune response |
| 02/10/2005 | US20050031617 Antibodies specific for cancer associated antigen SM5-1 and uses thereof |
| 02/10/2005 | US20050031615 For treating proliferative diseases characterized by neovascularization such as cancer, rheumatoid arthritis, psoriasis, proliferative retinopathy, and/or macular degeneration; rapid prevention of blood clotting via the extrinsic pathway; angiogenesis inhibitors |
| 02/10/2005 | US20050031614 Antibodies directed to parathyroid hormone (PTH) and uses thereof |
| 02/10/2005 | US20050031613 CD 16 antigen; antibody produced by cell unresistant to lectin which recognizes sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain; signal transduction |
| 02/10/2005 | US20050031609 Compositions for use in treating ige-associated disorders |
| 02/10/2005 | DE10333406A1 T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen T-regulatory cells containing galectins for the therapy and diagnosis of diseases |
| 02/10/2005 | CA2537899A1 Tissue-specific targeting of therapeutic and imaging agents to caveolae |
| 02/10/2005 | CA2534711A1 Combination therapies for multiple sclerosis |
| 02/10/2005 | CA2534639A1 Anti-cd19 antibodies |
| 02/10/2005 | CA2534360A1 Methods for expression and purification of immunotoxins |
| 02/10/2005 | CA2534353A1 Adipocyte complement related protein zacrp11 |
| 02/10/2005 | CA2534351A1 Accelerated vaccination |
| 02/10/2005 | CA2534299A1 System for producing dimeric proteins based on the escherichia coli hemolysin transport system |
| 02/10/2005 | CA2534077A1 Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| 02/10/2005 | CA2534055A1 Antibody cdr polypeptide sequences with restricted diversity |
| 02/10/2005 | CA2533918A1 Use of adcc-optimized antibodies for treating weak patients |
| 02/10/2005 | CA2533593A1 Altered antibodies having improved antigen-binding affinity |
| 02/10/2005 | CA2533559A1 Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof |
| 02/10/2005 | CA2533512A1 Antagonists and agonists of ldcam and methods of use |
| 02/10/2005 | CA2533297A1 Anti-vegf antibodies |
| 02/10/2005 | CA2532742A1 Use of a pak inhibitor for the treatment of a joint disease |
| 02/10/2005 | CA2531684A1 Binding molecules against sars-coronavirus and uses thereof |
| 02/10/2005 | CA2531329A1 Family of 28 kda babesia proteins as vaccines |
| 02/10/2005 | CA2531231A1 Uranium-chelating peptides and uses thereof |
| 02/10/2005 | CA2530172A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof |
| 02/10/2005 | CA2529798A1 Methods of treating hepatocellular carcinoma with zvegf3 antagonists |
| 02/09/2005 | EP1505149A1 Methylotroph producing mammalian type sugar chain |